Based on the aggregated intelligence of 170,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, drugmaker Isis Pharmaceuticals (Nasdaq: ISIS) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Isis' business and see what CAPS investors are saying about the stock right now.

Isis facts

Headquarters (Founded)

Carlsbad, Calif. (1989)

Market Cap

$872.3 million



Trailing-12-Month Revenue

$108.5 million


Founder/Chairman/CEO Dr. Stanley Crooke

COO/CFO B. Lynne Parshall

Return on Equity (Average, Past 3 Years)



$474.4 million / $144.3 million

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 95.5% of the 629 members who have rated Isis believe the stock will outperform the S&P 500 going forward. These bulls include cmario and pcstuck.

Late last year, cmario tapped Isis as a sensible way to go for growth: "Key antisense technology and substantial pipeline combined with ... cash to finance their development. Stock should double within a year."

Over the next five years, in fact, Isis is expected to grow its bottom line at a brisk rate of 30% annually. That's much faster than bigger biotech plays like Amgen (Nasdaq: AMGN) (7.6%), Biogen Idec (Nasdaq: BIIB) (8.8%), and Gilead Sciences (Nasdaq: GILD) (15%).

CAPS member pcstuck elaborates on the growth opportunity:

I like ISIS as a long term play. Small cap biotech with lots of promise and strong pipeline. At this price, the depth of their pipeline does not seem to be taken into account. As with all biotechs, a lot if left up in the air with the FDA and how trials go, but at this price i think the risk is worth it.

What do you think about Isis, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Gilead is a Motley Fool Stock Advisor selection. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.